Isaac Barchas, a director at $IMNM, sold 101,050 shares of the company on 06-30-2026 for an estimated $2,134,176. We received data on the trade from a recent SEC filing. This was a sale of approximately 24.7% of their shares of this class of stock. Following this trade, they now own 308,504 shares of this class of $IMNM stock.
$IMNM Insider Trading Activity
$IMNM insiders have traded $IMNM stock on the open market 20 times in the past 6 months. Of those trades, 7 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $IMNM stock by insiders over the last 6 months:
- ISAAC BARCHAS has made 0 purchases and 3 sales selling 201,050 shares for an estimated $4,393,024.
- MAX ROSETT (Chief Financial Officer) has made 0 purchases and 3 sales selling 125,000 shares for an estimated $2,518,716.
- PHILIP WAGENHEIM has made 0 purchases and 2 sales selling 65,000 shares for an estimated $1,335,626.
- ROBERT LECHLEIDER (Chief Medical Officer) has made 0 purchases and 2 sales selling 55,000 shares for an estimated $1,091,662.
- JEAN JACQUES BIENAIME has made 6 purchases buying 17,500 shares for an estimated $351,430 and 2 sales selling 10,500 shares for an estimated $203,820.
- CLAY B SIEGALL (President and CEO) purchased 25,450 shares for an estimated $500,601
- JACK HIGGINS (Chief Scientific Officer) sold 9,438 shares for an estimated $204,238
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IMNM Hedge Fund Activity
We have seen 104 institutional investors add shares of $IMNM stock to their portfolio, and 64 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 7,034,952 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $153,854,400
- WELLINGTON MANAGEMENT GROUP LLP added 3,797,514 shares (+406.4%) to their portfolio in Q1 2026, for an estimated $83,051,631
- ECOR1 CAPITAL, LLC removed 2,855,590 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $62,451,753
- CITADEL ADVISORS LLC removed 1,660,508 shares (-95.4%) from their portfolio in Q1 2026, for an estimated $36,315,309
- STATE STREET CORP added 1,531,901 shares (+39.6%) to their portfolio in Q1 2026, for an estimated $33,502,674
- BALYASNY ASSET MANAGEMENT L.P. removed 1,178,284 shares (-82.4%) from their portfolio in Q1 2026, for an estimated $25,769,071
- ENAVATE SCIENCES GP, LLC removed 1,154,784 shares (-24.2%) from their portfolio in Q1 2026, for an estimated $25,255,126
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$IMNM Analyst Ratings
Wall Street analysts have issued reports on $IMNM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/12/2026
- Wedbush issued a "Outperform" rating on 01/15/2026
To track analyst ratings and price targets for $IMNM, check out Quiver Quantitative's $IMNM forecast page.
$IMNM Price Targets
Multiple analysts have issued price targets for $IMNM recently. We have seen 7 analysts offer price targets for $IMNM in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- David Nierengarten from Wedbush set a target price of $31.0 on 06/12/2026
- Lukas Shumway from Barclays set a target price of $36.0 on 05/28/2026
- Supawat Thongthip from Truist Securities set a target price of $37.0 on 05/28/2026
- Andrew Berens from Leerink Partners set a target price of $33.0 on 05/15/2026
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $40.0 on 05/13/2026
- Sudan Loganathan from Stephens & Co. set a target price of $30.0 on 03/04/2026
- Adam Vogel from Craig-Hallum set a target price of $36.0 on 03/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
